<DOC>
	<DOCNO>NCT01204814</DOCNO>
	<brief_summary>MTN-009 multi-site , cross-sectional study provide estimate prevalence ARV resistance population woman present study sit pre-screened screened participation HIV prevention trial . To date , comprehensive surveillance HIV drug resistance newly diagnose woman reproductive age yet undertake . The primary goal MTN-009 ass frequency HIV drug resistance mutation among woman test HIV-positive presenting screen participation HIV prevention trial .</brief_summary>
	<brief_title>HIV-1 Resistance Screening HIV Prevention Studies</brief_title>
	<detailed_description>MTN-009 multi-site , cross-sectional study provide estimate prevalence ARV resistance population woman present study sit pre-screened screened participation HIV prevention trial . To date , comprehensive surveillance HIV drug resistance newly diagnose woman reproductive age yet undertake . The primary goal MTN-009 ass frequency HIV drug resistance mutation among woman test HIV-positive presenting screen participation HIV prevention trial . Secondary aim include identification evaluation behavioral indicator include self sexual partner ( ) exposures antiretroviral ( ARV ) drug risk factor drug resistant HIV infection , well characterization degree immunodeficiency risk disease progression quantify plasma HIV-1 RNA CD4-positive T cell among woman test HIV-positive presenting screen participation HIV prevention trial . Exploratory aim include identification polymorphic subtype-specific sequence change HIV-1 may impact susceptibility ARVs , estimation proportion HIV-positive woman chronic versus recent HIV infection . The finding significant resistance , lack thereof , ARV-based study product deliver vaginally take orally may guide decision related future microbicide PrEP study . In addition , MTN-009 provide valuable comparison data resistance data obtain MTN-015 , MTN seroconverter study .</detailed_description>
	<criteria>Present MTN009 study site prescreen screen HIV prevention trial Age 1840 year , verify per site standard operating procedure ( SOP ) Able willing provide write informed consent participation MTN009 Able willing provide adequate locator information , define site SOPs Any condition , investigator 's opinion , would preclude informed consent , make study participation unsafe , complicate interpretation study outcome data , otherwise interfere achievement study objective</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>HIV</keyword>
	<keyword>Drug resistance</keyword>
	<keyword>mutation</keyword>
	<keyword>ARV 's</keyword>
</DOC>